NZ599968A - Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity - Google Patents
Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activityInfo
- Publication number
- NZ599968A NZ599968A NZ599968A NZ59996810A NZ599968A NZ 599968 A NZ599968 A NZ 599968A NZ 599968 A NZ599968 A NZ 599968A NZ 59996810 A NZ59996810 A NZ 59996810A NZ 599968 A NZ599968 A NZ 599968A
- Authority
- NZ
- New Zealand
- Prior art keywords
- ddr1
- ddr2
- bcr
- pdgf
- kit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26181209P | 2009-11-17 | 2009-11-17 | |
PCT/US2010/056926 WO2011062927A1 (en) | 2009-11-17 | 2010-11-17 | Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ599968A true NZ599968A (en) | 2014-09-26 |
Family
ID=43513643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ599968A NZ599968A (en) | 2009-11-17 | 2010-11-17 | Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity |
Country Status (37)
Country | Link |
---|---|
US (1) | US9061029B2 (it) |
EP (1) | EP2501384B2 (it) |
JP (2) | JP5829615B2 (it) |
KR (1) | KR101743315B1 (it) |
CN (1) | CN102612368B (it) |
AR (1) | AR079029A1 (it) |
AU (1) | AU2010322102B2 (it) |
BR (1) | BR112012011693A2 (it) |
CA (1) | CA2779490C (it) |
CL (1) | CL2012001270A1 (it) |
CO (1) | CO6551690A2 (it) |
DK (1) | DK2501384T4 (it) |
EC (1) | ECSP12011903A (it) |
ES (1) | ES2572128T5 (it) |
FI (1) | FI2501384T4 (it) |
GT (1) | GT201200150A (it) |
HK (1) | HK1169950A1 (it) |
HR (1) | HRP20160472T4 (it) |
HU (1) | HUE027307T2 (it) |
IL (1) | IL219727A (it) |
JO (1) | JO3634B1 (it) |
MA (1) | MA33738B1 (it) |
ME (1) | ME02413B (it) |
MX (1) | MX2012005694A (it) |
MY (1) | MY169956A (it) |
NZ (1) | NZ599968A (it) |
PE (1) | PE20121476A1 (it) |
PL (1) | PL2501384T5 (it) |
RS (1) | RS54747B2 (it) |
RU (1) | RU2625835C2 (it) |
SG (1) | SG10201501169VA (it) |
SI (1) | SI2501384T2 (it) |
SM (1) | SMT201600143B (it) |
TN (1) | TN2012000206A1 (it) |
TW (1) | TWI498116B (it) |
WO (1) | WO2011062927A1 (it) |
ZA (1) | ZA201203328B (it) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2776130A1 (en) | 2011-11-07 | 2014-09-17 | Institut National de la Sante et de la Recherche Medicale (INSERM) | A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis |
TW201348187A (zh) | 2012-04-24 | 2013-12-01 | Chugai Pharmaceutical Co Ltd | 苯甲醯胺衍生物 |
TW201348213A (zh) * | 2012-04-24 | 2013-12-01 | Chugai Pharmaceutical Co Ltd | 喹唑啉二酮衍生物 |
EP4238566A1 (en) | 2012-05-02 | 2023-09-06 | Georgetown University | Treating amyotrophic lateral sclerosis with tyrosine kinase inhibitors |
PE20210667A1 (es) * | 2012-05-15 | 2021-04-05 | Novartis Ag | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 |
US9561245B2 (en) | 2012-09-06 | 2017-02-07 | The Board Of Regents Of The University Of Texas System | Combination treatments for melanoma |
US20140080772A1 (en) * | 2012-09-06 | 2014-03-20 | The Board Of Regents Of The University Of Texas System | Treatments for melanoma |
US9572828B2 (en) | 2013-07-18 | 2017-02-21 | The Board Of Regents Of The University Of Texas System | Treatment for melanoma |
CN105829285A (zh) | 2013-10-23 | 2016-08-03 | 中外制药株式会社 | 喹唑啉酮和异喹啉酮衍生物 |
CN107922320A (zh) * | 2015-08-31 | 2018-04-17 | 东丽株式会社 | 尿素衍生物和其用途 |
CN108103186B (zh) * | 2018-02-28 | 2021-07-02 | 固安博健生物技术有限公司 | 诊断类风湿性关节炎和骨关节炎的分子标志物 |
TWI770624B (zh) | 2018-06-15 | 2022-07-11 | 漢達生技醫藥股份有限公司 | 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途 |
WO2020144647A1 (en) * | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Pharmaceutical composition comprising apalutamide dispersed in apple sauce |
IL295007A (en) | 2020-01-31 | 2022-09-01 | Nanocopoeia Llc | Amorphous nilotinib microparticles and uses thereof |
EP4142699A1 (en) | 2020-04-30 | 2023-03-08 | Nanocopoeia LLC | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003246100A1 (en) | 2002-06-28 | 2004-01-19 | Nippon Shinyaku Co., Ltd. | Amide derivative |
GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
JP4664071B2 (ja) * | 2002-08-01 | 2011-04-06 | エーザイ コーポレーション オブ ノース アメリカ | グルタミンによるガンの改良治療 |
US20080176879A1 (en) * | 2005-05-02 | 2008-07-24 | Leila Alland | Pyrimidylaminobenzamide Derivatives For Sytemic Mastocytosis |
SA06270147B1 (ar) | 2005-06-09 | 2009-12-22 | نوفارتيس ايه جي | عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين |
GT200600316A (es) | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
GT200600315A (es) | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
EP1923053A1 (en) | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
KR100925559B1 (ko) * | 2007-10-26 | 2009-11-05 | 한국과학기술연구원 | 악티노마이신 d를 유효성분으로 하는 ddr과 콜라겐결합 저해제 |
-
2010
- 2010-11-14 JO JOP/2010/0396A patent/JO3634B1/ar active
- 2010-11-15 AR ARP100104212A patent/AR079029A1/es not_active Application Discontinuation
- 2010-11-16 TW TW099139425A patent/TWI498116B/zh active
- 2010-11-17 FI FIEP10781781.9T patent/FI2501384T4/fi active
- 2010-11-17 KR KR1020127012603A patent/KR101743315B1/ko active IP Right Grant
- 2010-11-17 DK DK10781781.9T patent/DK2501384T4/da active
- 2010-11-17 RS RS20160303A patent/RS54747B2/sr unknown
- 2010-11-17 ES ES10781781T patent/ES2572128T5/es active Active
- 2010-11-17 NZ NZ599968A patent/NZ599968A/en unknown
- 2010-11-17 HR HRP20160472TT patent/HRP20160472T4/hr unknown
- 2010-11-17 AU AU2010322102A patent/AU2010322102B2/en active Active
- 2010-11-17 PE PE2012000667A patent/PE20121476A1/es not_active Application Discontinuation
- 2010-11-17 MY MYPI2012001993A patent/MY169956A/en unknown
- 2010-11-17 PL PL10781781.9T patent/PL2501384T5/pl unknown
- 2010-11-17 RU RU2012124811A patent/RU2625835C2/ru active
- 2010-11-17 EP EP10781781.9A patent/EP2501384B2/en active Active
- 2010-11-17 CN CN201080051819.0A patent/CN102612368B/zh active Active
- 2010-11-17 BR BR112012011693A patent/BR112012011693A2/pt not_active Application Discontinuation
- 2010-11-17 HU HUE10781781A patent/HUE027307T2/hu unknown
- 2010-11-17 US US13/509,626 patent/US9061029B2/en active Active
- 2010-11-17 JP JP2012539982A patent/JP5829615B2/ja active Active
- 2010-11-17 SI SI201031172T patent/SI2501384T2/sl unknown
- 2010-11-17 SG SG10201501169VA patent/SG10201501169VA/en unknown
- 2010-11-17 WO PCT/US2010/056926 patent/WO2011062927A1/en active Application Filing
- 2010-11-17 CA CA2779490A patent/CA2779490C/en active Active
- 2010-11-17 ME MEP-2016-89A patent/ME02413B/me unknown
- 2010-11-17 MX MX2012005694A patent/MX2012005694A/es active IP Right Grant
-
2012
- 2012-05-07 TN TNP2012000206A patent/TN2012000206A1/en unknown
- 2012-05-08 ZA ZA2012/03328A patent/ZA201203328B/en unknown
- 2012-05-10 IL IL219727A patent/IL219727A/en active IP Right Grant
- 2012-05-11 MA MA34855A patent/MA33738B1/fr unknown
- 2012-05-16 EC ECSP12011903 patent/ECSP12011903A/es unknown
- 2012-05-16 CL CL2012001270A patent/CL2012001270A1/es unknown
- 2012-05-17 CO CO12081907A patent/CO6551690A2/es not_active Application Discontinuation
- 2012-05-17 GT GT201200150A patent/GT201200150A/es unknown
- 2012-10-26 HK HK12110734.6A patent/HK1169950A1/zh active IP Right Maintenance
-
2015
- 2015-04-28 JP JP2015091857A patent/JP2015180636A/ja active Pending
-
2016
- 2016-05-23 SM SM201600143T patent/SMT201600143B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ599968A (en) | Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity | |
NZ599217A (en) | Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity | |
PH12015501483A1 (en) | Heterocyclic compounds and uses thereof | |
HRP20182059T1 (hr) | Polimorfi i soli 6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1h-indazola kao inhibitori pi3k, namijenjeni upotrebi u liječenju, primjerice, dišnih poremećaja | |
NZ593114A (en) | Compounds comprising benzimidazolyl, pyrimidinyl, and pyridinyl moieties which are useful as protein kinase inhibitors | |
MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
NZ591449A (en) | Picolinamide derivatives as kinase inhibitors | |
SI2981533T1 (en) | Protein Protein Kinase | |
NZ588830A (en) | Inhibitors of protein kinases | |
MX2009004807A (es) | Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa. | |
MX2009009592A (es) | Aminopiridinas utiles como inhibidores de proteinas cinasas. | |
NZ627560A (en) | Heterocyclic piperazine compounds and methods for their use | |
MX2014011188A (es) | Compuestos y metodos para el tratamiento de trastornos celulares adrenocorticales aberrantes. | |
RU2012147511A (ru) | Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза | |
NZ603859A (en) | Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferative disorders | |
IN2014DN03416A (it) | ||
MX2012008611A (es) | Sales farmaceuticas aceptables de derivados heterociclicos pirrolo-nitrogenosos, su metodo de preparacion y uso medico. | |
CY1117519T1 (el) | Μεθοδος θεραπειας πολλαπλασιαστικων διαταραχων και αλλων παθολογικων καταστασεων που προκαλουνται απο bcr-abl, c-kit, ddr1, ddr2 ή pdgf-r δραστηριοτητα κινασης | |
TH135810A (th) | วิธีการของการรักษาความผิดปกติด้านงอกขยาย และ สภาวะในทางพยาธิวิทยาอื่นๆ ที่สื่อผ่านจาก bcr-abl,c-kit,ddr1,ddr2 หรือ pdgf-r ไคเนส แอคตีวิตี้ | |
RU2013142924A (ru) | Вещества, ингибирующие переносчик глицина | |
TH135810B (th) | วิธีการของการรักษาความผิดปกติด้านงอกขยาย และ สภาวะในทางพยาธิวิทยาอื่นๆ ที่สื่อผ่านจาก bcr-abl,c-kit,ddr1,ddr2 หรือ pdgf-r ไคเนส แอคตีวิตี้ | |
NZ621583A (en) | Ethynyl derivatives as metabotropic glutamate receptor modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ERR | Error or correction |
Free format text: THE OWNER HAS BEEN CORRECTED TO 890887, NOVARTIS AG, LICHTSTRASSE 35, CH-4056 BASEL, CH Effective date: 20140409 |
|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 NOV 2017 BY BALDWINS INTELLECTUAL PROPERTY Effective date: 20150112 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2018 BY CPA GLOBAL Effective date: 20171019 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2019 BY CPA GLOBAL Effective date: 20181018 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2020 BY CPA GLOBAL Effective date: 20191017 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2021 BY CPA GLOBAL Effective date: 20201022 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2022 BY CPA GLOBAL Effective date: 20211022 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2023 BY CPA GLOBAL Effective date: 20221020 |